# To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

> **NCT07684820** · PHASE2 · RECRUITING · sponsor: **Expedition Therapeutics, Inc** · enrollment: 600 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** EXPD-101/FXS7553 Dose 1
- **DRUG:** EXPD-101/FXS7553 Dose 2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07684820
- **Lead sponsor:** Expedition Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-07-11
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07684820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07684820, "To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07684820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*